JP2017534638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534638A5 JP2017534638A5 JP2017524049A JP2017524049A JP2017534638A5 JP 2017534638 A5 JP2017534638 A5 JP 2017534638A5 JP 2017524049 A JP2017524049 A JP 2017524049A JP 2017524049 A JP2017524049 A JP 2017524049A JP 2017534638 A5 JP2017534638 A5 JP 2017534638A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- pharmaceutical composition
- mammal
- bcva
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims description 37
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims description 23
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 23
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 23
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 23
- 239000005557 antagonist Substances 0.000 claims description 23
- 230000009266 disease activity Effects 0.000 claims description 20
- 208000031513 cyst Diseases 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 230000004304 visual acuity Effects 0.000 claims description 14
- 210000001525 retina Anatomy 0.000 claims description 12
- 206010011732 Cyst Diseases 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076770P | 2014-11-07 | 2014-11-07 | |
| US62/076,770 | 2014-11-07 | ||
| US201462088061P | 2014-12-05 | 2014-12-05 | |
| US62/088,061 | 2014-12-05 | ||
| PCT/US2015/059575 WO2016073918A1 (en) | 2014-11-07 | 2015-11-06 | Methods for treating ocular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020138531A Division JP2020193212A (ja) | 2014-11-07 | 2020-08-19 | 眼疾患を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534638A JP2017534638A (ja) | 2017-11-24 |
| JP2017534638A5 true JP2017534638A5 (show.php) | 2018-12-06 |
| JP6753848B2 JP6753848B2 (ja) | 2020-09-09 |
Family
ID=54697654
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523878A Active JP6667519B2 (ja) | 2014-11-07 | 2015-11-06 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
| JP2017524049A Active JP6753848B2 (ja) | 2014-11-07 | 2015-11-06 | 眼疾患を処置する方法 |
| JP2020000823A Active JP7080263B2 (ja) | 2014-11-07 | 2020-01-07 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
| JP2020138531A Withdrawn JP2020193212A (ja) | 2014-11-07 | 2020-08-19 | 眼疾患を処置する方法 |
| JP2022119423A Pending JP2022141923A (ja) | 2014-11-07 | 2022-07-27 | 眼疾患を処置する方法 |
| JP2024170733A Pending JP2025004075A (ja) | 2014-11-07 | 2024-09-30 | 眼疾患を処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523878A Active JP6667519B2 (ja) | 2014-11-07 | 2015-11-06 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000823A Active JP7080263B2 (ja) | 2014-11-07 | 2020-01-07 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
| JP2020138531A Withdrawn JP2020193212A (ja) | 2014-11-07 | 2020-08-19 | 眼疾患を処置する方法 |
| JP2022119423A Pending JP2022141923A (ja) | 2014-11-07 | 2022-07-27 | 眼疾患を処置する方法 |
| JP2024170733A Pending JP2025004075A (ja) | 2014-11-07 | 2024-09-30 | 眼疾患を処置する方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US10035850B2 (show.php) |
| EP (2) | EP3215123A1 (show.php) |
| JP (6) | JP6667519B2 (show.php) |
| KR (4) | KR20240161204A (show.php) |
| CN (4) | CN106999581A (show.php) |
| AU (6) | AU2015342818B2 (show.php) |
| BR (2) | BR112017008093A2 (show.php) |
| CA (1) | CA2966646A1 (show.php) |
| CL (2) | CL2017001117A1 (show.php) |
| CO (1) | CO2017004596A2 (show.php) |
| EA (1) | EA201790989A1 (show.php) |
| EC (1) | ECSP17034829A (show.php) |
| ES (1) | ES3051145T3 (show.php) |
| GT (1) | GT201700096A (show.php) |
| IL (5) | IL251642B (show.php) |
| MX (3) | MX383808B (show.php) |
| MY (2) | MY183807A (show.php) |
| NZ (1) | NZ730821A (show.php) |
| PE (1) | PE20170780A1 (show.php) |
| PH (3) | PH12021550147A1 (show.php) |
| RU (1) | RU2722643C2 (show.php) |
| SG (3) | SG11201702954XA (show.php) |
| TN (1) | TN2017000128A1 (show.php) |
| TW (4) | TWI738632B (show.php) |
| WO (2) | WO2016073918A1 (show.php) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| EP2307458B1 (en) | 2008-06-25 | 2018-04-11 | ESBATech, an Alcon Biomedical Research Unit LLC | Humanization of rabbit antibodies using a universal antibody framework |
| HUE053548T2 (hu) | 2008-06-25 | 2021-07-28 | Novartis Ag | Stabil és szolúbilis, TNF-gátló ellenanyagok |
| TR201907783T4 (tr) | 2009-07-06 | 2019-06-21 | Aerpio Therapeutics Inc | Benzosulfonamit türevleri, bileşimleri ve kanser hücrelerinin metastazının önlenmesinde kullanımları. |
| EP2663325A1 (en) | 2011-01-13 | 2013-11-20 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
| EP2766043A4 (en) | 2011-10-13 | 2015-06-10 | Aerpio Therapeutics Inc | METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| CN107206080B (zh) | 2015-01-28 | 2022-07-08 | 辉瑞公司 | 稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂 |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3977994B1 (en) | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| NZ782855A (en) | 2015-12-04 | 2025-08-29 | Novartis Ag | Compositions and methods for immunooncology |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| MX2019000727A (es) | 2016-07-20 | 2019-05-02 | Aerpio Therapeutics Inc | Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b). |
| US11254738B2 (en) * | 2016-09-07 | 2022-02-22 | The Governing Council Of The University Of Toronto Banting Institute | Synthetic antibodies against VEGF and their uses |
| EP3518971A4 (en) * | 2016-09-28 | 2020-05-13 | Board Of Regents, The University Of Texas System | ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF |
| RU2767793C2 (ru) | 2016-11-18 | 2022-03-21 | Астеллас Фарма Инк. | НОВЫЙ Fab-ФРАГМЕНТ АНТИТЕЛА ПРОТИВ MUC1 ЧЕЛОВЕКА |
| EP3601561A2 (en) | 2017-03-22 | 2020-02-05 | Novartis AG | Compositions and methods for immunooncology |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| WO2018195912A1 (zh) * | 2017-04-28 | 2018-11-01 | 苏州思坦维生物技术股份有限公司 | 一种眼用药物组合物及其用途 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| WO2019020777A1 (en) * | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| SG11202002489YA (en) | 2017-10-06 | 2020-04-29 | Prothena Biosciences Ltd | Anti-transthyretin antibodies |
| BR112020006791A2 (pt) | 2017-10-06 | 2020-12-01 | Prothena Biosciences Limited | métodos de detecção de transtirretina |
| CN111433223B (zh) * | 2017-11-29 | 2024-08-27 | 诺和诺德A/S（股份有限公司） | 抗甲状腺素运载蛋白单克隆抗体的冻干制剂 |
| KR20240074890A (ko) | 2017-11-30 | 2024-05-28 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| EA202091786A1 (ru) | 2018-01-26 | 2020-10-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс |
| KR20250166355A (ko) * | 2018-02-06 | 2025-11-27 | 에프. 호프만-라 로슈 아게 | 안과 질환의 치료 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| KR20200131839A (ko) * | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
| TW202003036A (zh) * | 2018-03-23 | 2020-01-16 | 德商艾伯維德國有限及兩合公司 | 穩定水性抗-tau抗體調配物 |
| CN112262158B (zh) * | 2018-04-10 | 2024-08-09 | 奥美药业有限公司 | 新型血管生成素2，vegf双特异性拮抗剂 |
| MX421310B (es) | 2018-05-10 | 2025-03-14 | Regeneron Pharma | Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración |
| CN112135841A (zh) | 2018-05-17 | 2020-12-25 | 安斯泰来制药株式会社 | 包含抗人MUC1抗体Fab片段、肽接头和/或配体的复合物 |
| US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
| TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣３多肽之持續遞送 |
| US12065503B2 (en) * | 2018-10-10 | 2024-08-20 | Astellas Pharma Inc. | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| CN119033685A (zh) * | 2018-10-29 | 2024-11-29 | 豪夫迈·罗氏有限公司 | 抗体制剂 |
| JP7487193B2 (ja) | 2018-11-07 | 2024-05-20 | アプライド モレキュラー トランスポート インコーポレイテッド | 異種ペイロードの経口送達のためのコリックス由来担体 |
| JP7089121B2 (ja) * | 2018-12-18 | 2022-06-21 | ノバルティス アーゲー | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| TW202532428A (zh) | 2019-04-26 | 2025-08-16 | 美商愛德維仁生物科技公司 | 用於玻璃體內遞送之變異體aav蛋白殼 |
| AU2020264969B2 (en) | 2019-04-29 | 2025-06-05 | EyePoint, Inc. | Tie-2 activators targeting the schlemm's canal |
| EP3844169B1 (en) | 2019-08-16 | 2025-10-01 | Thornhill Therapeutics, Inc. | Compositions, formulations, and interleukin production and purification |
| CN114786731A (zh) * | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| MX2022006241A (es) | 2019-11-25 | 2022-08-22 | Univ California | Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular. |
| CN111217834B (zh) * | 2020-02-21 | 2021-10-26 | 维眸生物科技（上海）有限公司 | Rock激酶抑制剂的硝基氧衍生物 |
| BR112022015627A2 (pt) * | 2020-03-04 | 2022-09-27 | Shanghai Henlius Biotech Inc | Formulação farmacêutica que compreende bevacizumabe |
| WO2021233408A1 (zh) * | 2020-05-21 | 2021-11-25 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其稳定制剂 |
| KR20220001106A (ko) * | 2020-06-29 | 2022-01-05 | (주)메디톡스 | 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체 |
| EP4182025A1 (en) | 2020-07-16 | 2023-05-24 | Novartis AG | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
| PL4185318T3 (pl) * | 2021-05-17 | 2026-01-12 | Regeneron Pharmaceuticals, Inc. | Rozszerzone schematy leczenia dużymi dawkami antagonistów vegf w leczeniu angiogennych zaburzeń oka |
| CN113940997B (zh) * | 2021-12-21 | 2022-04-08 | 迈威(上海)生物科技股份有限公司 | 一种双特异性抗体的稳定制剂 |
| WO2024056058A1 (zh) * | 2022-09-16 | 2024-03-21 | 齐鲁制药有限公司 | 一种稳定的高浓度自缓冲药物组合物 |
| WO2025231345A1 (en) * | 2024-05-03 | 2025-11-06 | Therini Bio, Inc. | Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| SI1802334T1 (sl) | 2004-10-21 | 2012-12-31 | Genentech, Inc. | Postopek za zdravljenje intraokularnih neovaskularnih bolezni |
| WO2007011873A2 (en) * | 2005-07-15 | 2007-01-25 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR101406811B1 (ko) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형 |
| PE20090329A1 (es) | 2007-05-30 | 2009-03-27 | Abbott Lab | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| EP2307458B1 (en) | 2008-06-25 | 2018-04-11 | ESBATech, an Alcon Biomedical Research Unit LLC | Humanization of rabbit antibodies using a universal antibody framework |
| HUE053548T2 (hu) | 2008-06-25 | 2021-07-28 | Novartis Ag | Stabil és szolúbilis, TNF-gátló ellenanyagok |
| ES2793008T3 (es) * | 2008-06-25 | 2020-11-12 | Novartis Ag | Anticuerpos estables y solubles que inhiben VEGF |
| WO2010006454A2 (en) | 2008-06-30 | 2010-01-21 | Esbatech, An Alcon Biomedical Research Unit Llc | Functionalized polypeptides |
| EP2515941B1 (en) | 2009-12-21 | 2019-11-13 | F.Hoffmann-La Roche Ag | Pharmaceutical formulation of bevacizumab |
| EP2648750B1 (en) | 2010-12-10 | 2017-01-25 | Novartis AG | Antibody formulation |
| EP2663325A1 (en) * | 2011-01-13 | 2013-11-20 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
| RU2013155695A (ru) * | 2011-06-30 | 2015-08-10 | Дженентек, Инк. | Препараты антител против с-мет |
| EP3431495A1 (en) * | 2011-10-20 | 2019-01-23 | ESBATech - a Novartis Company LLC | Stable multiple antigen-binding antibody |
| AU2013256092B2 (en) | 2012-05-03 | 2017-11-23 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| MY189047A (en) | 2013-03-13 | 2022-01-21 | Genentech Inc | Antibody formulations |
| WO2015086830A1 (en) * | 2013-12-13 | 2015-06-18 | Delenex Therapeutics Ag | Skin penetrating polypeptides |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| BR112016029864A2 (pt) * | 2014-06-17 | 2017-08-22 | Clearside Biomedical Inc | métodos e dispositivos para tratamento de desordens oculares posteriores. |
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| KR20200131839A (ko) | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
| JP7089121B2 (ja) | 2018-12-18 | 2022-06-21 | ノバルティス アーゲー | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 |
-
2015
- 2015-10-26 TW TW104135105A patent/TWI738632B/zh active
- 2015-10-26 TW TW104135104A patent/TWI705827B/zh active
- 2015-10-26 TW TW110133255A patent/TWI806150B/zh active
- 2015-10-26 TW TW109132401A patent/TWI761959B/zh active
- 2015-11-06 EP EP15807721.4A patent/EP3215123A1/en active Pending
- 2015-11-06 ES ES15798609T patent/ES3051145T3/es active Active
- 2015-11-06 BR BR112017008093-1A patent/BR112017008093A2/pt not_active Application Discontinuation
- 2015-11-06 EA EA201790989A patent/EA201790989A1/ru unknown
- 2015-11-06 PE PE2017000812A patent/PE20170780A1/es unknown
- 2015-11-06 US US14/934,731 patent/US10035850B2/en active Active
- 2015-11-06 RU RU2017119647A patent/RU2722643C2/ru active
- 2015-11-06 WO PCT/US2015/059575 patent/WO2016073918A1/en not_active Ceased
- 2015-11-06 CN CN201580060665.4A patent/CN106999581A/zh active Pending
- 2015-11-06 AU AU2015342818A patent/AU2015342818B2/en active Active
- 2015-11-06 KR KR1020247035792A patent/KR20240161204A/ko not_active Ceased
- 2015-11-06 BR BR112017008660A patent/BR112017008660A2/pt not_active Application Discontinuation
- 2015-11-06 JP JP2017523878A patent/JP6667519B2/ja active Active
- 2015-11-06 CA CA2966646A patent/CA2966646A1/en active Pending
- 2015-11-06 KR KR1020177014978A patent/KR102588846B1/ko active Active
- 2015-11-06 MY MYPI2017701217A patent/MY183807A/en unknown
- 2015-11-06 KR KR1020237014727A patent/KR102724014B1/ko active Active
- 2015-11-06 MX MX2017005874A patent/MX383808B/es unknown
- 2015-11-06 SG SG11201702954XA patent/SG11201702954XA/en unknown
- 2015-11-06 MX MX2017005875A patent/MX383399B/es unknown
- 2015-11-06 KR KR1020177012256A patent/KR20170082526A/ko not_active Ceased
- 2015-11-06 WO PCT/US2015/059571 patent/WO2016073915A1/en not_active Ceased
- 2015-11-06 TN TN2017000128A patent/TN2017000128A1/en unknown
- 2015-11-06 NZ NZ73082115A patent/NZ730821A/en unknown
- 2015-11-06 CN CN201580060416.5A patent/CN107635580A/zh active Pending
- 2015-11-06 AU AU2015342815A patent/AU2015342815B2/en active Active
- 2015-11-06 MY MYPI2020002268A patent/MY193913A/en unknown
- 2015-11-06 US US14/934,666 patent/US10689438B2/en active Active
- 2015-11-06 SG SG10201913565RA patent/SG10201913565RA/en unknown
- 2015-11-06 CN CN202511153148.3A patent/CN120938921A/zh active Pending
- 2015-11-06 CN CN202111376360.8A patent/CN114081951A/zh active Pending
- 2015-11-06 PH PH1/2021/550147A patent/PH12021550147A1/en unknown
- 2015-11-06 JP JP2017524049A patent/JP6753848B2/ja active Active
- 2015-11-06 EP EP15798609.2A patent/EP3215122B1/en active Active
- 2015-11-06 SG SG11201702909QA patent/SG11201702909QA/en unknown
-
2017
- 2017-04-06 IL IL251642A patent/IL251642B/en active IP Right Grant
- 2017-04-12 IL IL251696A patent/IL251696A0/en active IP Right Grant
- 2017-05-04 MX MX2021006768A patent/MX2021006768A/es unknown
- 2017-05-05 CO CONC2017/0004596A patent/CO2017004596A2/es unknown
- 2017-05-05 GT GT201700096A patent/GT201700096A/es unknown
- 2017-05-05 CL CL2017001117A patent/CL2017001117A1/es unknown
- 2017-05-05 PH PH12017500843A patent/PH12017500843A1/en unknown
- 2017-05-05 PH PH12017500844A patent/PH12017500844B1/en unknown
- 2017-05-05 CL CL2017001115A patent/CL2017001115A1/es unknown
- 2017-06-05 EC ECIEPI201734829A patent/ECSP17034829A/es unknown
-
2018
- 2018-06-26 US US16/018,244 patent/US11098110B2/en active Active
- 2018-12-04 AU AU2018274882A patent/AU2018274882B2/en active Active
- 2018-12-11 AU AU2018278870A patent/AU2018278870B2/en active Active
-
2019
- 2019-03-20 IL IL265497A patent/IL265497B/en active IP Right Grant
-
2020
- 2020-01-07 JP JP2020000823A patent/JP7080263B2/ja active Active
- 2020-05-11 US US16/871,765 patent/US12049495B2/en active Active
- 2020-08-19 JP JP2020138531A patent/JP2020193212A/ja not_active Withdrawn
- 2020-08-21 AU AU2020220210A patent/AU2020220210B2/en active Active
- 2020-10-05 AU AU2020244614A patent/AU2020244614B2/en active Active
-
2021
- 2021-01-11 IL IL280087A patent/IL280087B/en unknown
- 2021-05-30 IL IL283561A patent/IL283561B/en unknown
- 2021-07-16 US US17/378,618 patent/US12371481B2/en active Active
-
2022
- 2022-07-27 JP JP2022119423A patent/JP2022141923A/ja active Pending
-
2024
- 2024-09-30 JP JP2024170733A patent/JP2025004075A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534638A5 (show.php) | ||
| RU2017119647A (ru) | Способ лечения болезней глаз | |
| JP2017501129A5 (show.php) | ||
| JP2016513075A5 (show.php) | ||
| EP4279135A3 (en) | Use of a vegf antagonist to treat diabetic retinopathy | |
| Lee et al. | Effect of a broad-specificity chemokine-binding protein on brain leukocyte infiltration and infarct development | |
| JP2019511222A5 (show.php) | ||
| JP2021509668A (ja) | 免疫抑制なしにｉｌ−６媒介性炎症を処置する方法 | |
| JP2015522576A5 (show.php) | ||
| JP2016538885A5 (show.php) | ||
| JP2010509369A5 (show.php) | ||
| WO2020097511A3 (en) | Messenger rna therapy for treatment of ocular diseases | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| JP2015528454A5 (show.php) | ||
| JP2017503820A5 (show.php) | ||
| JP2016521712A5 (show.php) | ||
| JP2017523776A5 (show.php) | ||
| JP2018529661A5 (show.php) | ||
| JP2016520615A5 (show.php) | ||
| JP2017535285A5 (show.php) | ||
| JP2018534259A5 (show.php) | ||
| JP2017503014A5 (show.php) | ||
| JP2019528285A5 (show.php) | ||
| JP2018530574A5 (show.php) | ||
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM |